Cyclooxygenase-2 Inhibitor Treatment Improves Left Ventricular Function and Mortality in a Murine Model of Doxorubicin-Induced Heart Failure

Circulation

Volumn 109, Issue 11, 2004, Pages 1428-1433

  Delgado III, Reynolds M ^a   Nawar, Mohamad A ^a   Zewail, Aly M ^a   Kar, Biswajit ^a   Vaughn, William K ^a   Wu, Kenneth K ^c   Aleksic, Nena ^c   Sivasubramanian, Natarajan ^b   McKay, Kathleen ^a   Mann, Douglas L ^b   Willerson, James T ^a,c  

^a ST LUKE S EPISCOPAL HOSPITAL   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Heart failure; Imaging; Inhibitors

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; DOXORUBICIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATTENUATION; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DISEASE COURSE; DISEASE MODEL; DOSE TIME EFFECT RELATION; DRUG INDUCED DISEASE; ENZYME INHIBITION; HEART CATHETERIZATION; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE INJURY; IMMUNOBLOTTING; INFLAMMATION; INTRAVASCULAR ULTRASOUND; MORTALITY; MOUSE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; STATISTICAL SIGNIFICANCE; TRANSTHORACIC ECHOCARDIOGRAPHY;

ANIMALS; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DISEASE PROGRESSION; DOXORUBICIN; DRUG EVALUATION, PRECLINICAL; FURANS; HEART FAILURE, CONGESTIVE; INFLAMMATION MEDIATORS; ISOENZYMES; MICE; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; REPRODUCIBILITY OF RESULTS; SINGLE-BLIND METHOD; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR FUNCTION, LEFT;

EID: 12144287870     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000121354.34067.48     Document Type: Article

References (29)

1. Kannel WB, Belanger AJ. AHA heart and stroke statistical update. Am Heart J. 1991;121:951-957.
2. Delgado RM, Massin EK. Congestive heart failure: when to consider new therapies. Managed Care Interface. 1998;11:71-75.
3. MacGowan GA, Mann DL, Kormos RL, et al. Circulating interleukin-6 in severe heart failure. Am J Cardiol. 1997;79:1128-1131.
4. Torre-Amione G, Kapadia S, Benedict C, et al. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol. 1996;27:1201-1206.
5. Torre-Amione G, Kapadia S, Lee J, et al. Tumor necrosis factor-alpha and tumor necrosis factor receptors in the failing human heart. Circulation. 1996;93:704-711.
6. Munger MA, Johnson B, Amber IJ, et al. Circulating concentrations of proinflammatory cytokines in mild or moderate heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol. 1996;77:723-727.
7. Devaux B, Scholz D, Hirche A, et al. Upregulation of cell adhesion molecules and the presence of low grade inflammation in human chronic heart failure. Eur Heart J. 1997;18:470-479.
8. Sasayama S, Matsumori A, Matoba Y, et al. Immunomodulation: a new horizon for medical treatment of heart failure. J Card Fail. 1996;2(suppl):S287-S294.
9. Matsumori A, Sasayama S. Immunomodulating agents for the management of heart failure with myocarditis and cardiomyopathy: lessons from animal experiments. Eur Heart J. 1995;16(suppl O):140-143.
10. Wong SC, Fukuchi M, Melnyk P, et al. Induction of cyclooxygenase-2 and activation of nuclear factor-κB in myocardium of patients with congestive heart failure. Circulation. 1998;98:100-103.
11. Spinale FG, Coker ML, Thomas CV, et al. Time-dependent changes in matrix metalloproteinase activity and expression during the progression of congestive heart failure: relation to ventricular and myocyte function. Circ Res. 1998;82:482-495.
12. Gilbert SJ, Wotton PR, Tarlton JF, et al. Increased expression of promatrix metalloproteinase-9 and neutrophil elastase in canine dilated cardiomyopathy. Cardiovasc Res. 1997;34:377-383.
13. Gunja-Smith Z, Morales AR, Romanelli R, et al. Remodeling of human myocardial collagen in idiopathic dilated cardiomyopathy: role of metalloproteinases and pyridinoline cross-links. Am J Pathol. 1996;148:1639-1648.
14. Kruse-Elliot KT, Olson NC. CGS 8515 and indomethacin attenuate cytokine-induced cardiopulmonary dysfunction in pigs. Am J Physiol. 1993;264(pt 2):H1076-H1086.
15. Townsend JN, Doran J, Lote CJ, et al. Peripheral hemodynamic effect of inhibition of prostaglandin synthesis in congestive heart failure and interaction with captopril. Br Heart J. 1995;73:434-441.
16. Van Acker SA, Kramer K, Voest EE, et al. Doxorubicin-induced cardiotoxicity monitored by ECG in freely moving mice: a new model to test potential protectors. Cancer Chemother Pharmacol. 1996;38:95-101.
17. Oshima M, Dinchuk JE, Kargmon S, et al. Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell. 1996;87:803-809.
18. Gilroy DW, Saunders MA, Sansores-Garcia L, et al. Cell cycle-dependent expression of cyclooxygenase-2 in human fibroblasts. FASEB J. 2001;15:288-290.
19. Wooding WM. Planning Pharmaceutical Clinical Trials. New York, NY: John Wiley & Sons; 1994:414-415.
20. Lee JK, Zaidi SH, Liu P, et al. A serine elastase inhibitor reduces inflammation and fibrosis and preserves cardiac function after experimentally-induced murine myocarditis. Nat Med. 1998;4:1383-1391.
21. Rao VU, Spinale FG. Controlling myocardial matrix remodeling: implications for heart failure. Cardiol Rev. 1999;7:136-143.
22. Mann DL, Spinale FG. Activation of matrix metalloproteinases in the failing heart. Circulation. 1998;98:1699-1702.
23. Thomas CV, Coker ML, Zellner JL, et al. Increased matrix metalloproteinase activity and selective upregulation in LV myocardium from patients with end-stage dilated cardiomyopathy. Circulation. 1998;97:1708-1715.
24. Lange LG, Schreiner GF. Immune mechanisms of cardiac disease. N Engl J Med. 1994;330:1129-1135.
25. Hasper D, Hummel M, Kleber FX, et al. Systemic inflammation in patients with heart failure. Eur Heart J. 1998;19:761-765.
26. Hawkey CJ. COX-2 inhibitors. Lancet. 1999;353:307-314.
27. Golden BD, Abramson SB. Selective cyclooxygenase-2 inhibitors. Rheum Dis Clin North Am. 1999;25:359-378.
28. Dowd NP, Scully M, Adderley SR, et al. Inhibition of cyclooxygenase-2 aggravates doxorubicin-mediated cardiac injury in vivo. J Clin Invest. 2001;108:585-590.
29. Adderley SR, Fitzgerald DJ. Oxidative damage of cardiomyocytes is limited by extracellular regulated kinases 1/2-mediated induction of cyclooxygenase-2. J Biol Chem. 1999;274:5038-5046.